FIGURE

Fig. 4

ID

ZDB-FIG-240411-22

Publication

Liu et al., 2024 - Targeting CD38/cyclic ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

Targets identification of ZGS II, BA, and DMA against leukopenia through network pharmacology. (A) ZGSII/BA/DMA-leukopenia-target networks. (B) Common targets of the compounds (ZGSII, BA, DMA) and leukopenia. (C) Protein-protein interaction (PPI) network of the bioactive compounds against leukopenia. (D) The top 12 biological processes of core targets for ZGSII, DMA, and BA against leukopenia, and (E) the related genes correspond to GO terms. (F-H) RTsingle bondqPCR validation of selected predicted genes (IFN-γ, IL-2, CEBP-β). (I) Western blot analysis and quantification of IFN-γ expression in NB4 cells treated with ZGSⅡ, BA, DMA, or C3G for 5 days. Data represent the mean ± SD of three independent experiments. * p < 0.05, * * p < 0.01, * ** p < 0.001 versus as indicated (one-way analysis of variance). (J) Top 20 enriched KEGG pathways of core targets for ZGSII, BA, and DMA against leukopenia.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Pharmacol. Res.